Troels H. Borch

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

Journal: Journal for immunotherapy of cancer

Published: July 27, 2026

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2026

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 22, 2026

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal: Journal of the National Cancer Institute

Published: March 09, 2026

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Journal: International journal of cancer

Published: January 28, 2026

Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma.

Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma.

Journal: Immuno-oncology technology

Published: January 23, 2026

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 24, 2025

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 27, 2025

Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 27, 2025

Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.

Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.

Journal: International journal of cancer

Published: September 16, 2025

The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma.

The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma.

Journal: American journal of clinical dermatology

Published: July 03, 2025

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Journal: Journal of the National Cancer Institute

Published: June 24, 2025

Showing 1-12 of 45

Last Updated: 09/26/2026